PubMed · 10188762
Lamifiban.
Abstract
Lamifiban is an intravenously administered, selective, reversible, nonpeptide glycoprotein IIb/IIIa receptor antagonist which inhibits platelet aggregation and thrombus formation by preventing the binding of fibrinogen to platelets. In trials in patients with non-Q wave myocardial infarction (MI) or unstable angina pectoris (PARAGON A and the Canadian Lamifiban Study), the incidence of clinical events at 30 days in patients receiving lamifiban (1 to 5 microg/min) was not significantly different from that in patients receiving aspirin plus heparin or aspirin alone. In PARAGON A, the incidence of clinical events at 6 months was significantly lower after lamifiban (with or without heparin) and aspirin therapy than after standard heparin and aspirin therapy. A large phase III trial (PARAGON B) is under way comparing lamifiban plus aspirin and heparin with standard aspirin and heparin therapy in patients with non-Q wave MI or unstable angina pectoris. In clinical trials, the most common adverse events associated with lamifiban were bleeding complications which were increased by the concomitant administration of heparin.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
M Dooley, K L Goa. 1999. Lamifiban.. https://doi.org/10.2165/00003495-199957020-00009
Cite the original work for its findings. Save a collection to share your selection of sources.